TMPRSS4 and neoplasm: Kim developed a novel TMPRSS4-cleavable peptide (TCP)-based liposome (TCP-L) that utilized the proteolytic activity of tumor-overexpressed transmembrane protease TMPRSS4 for targeted drug delivery.